India, Dec. 5 -- At the R&D Day, Novartis AG (NVS) stated that approximately 90 innovative new molecular entities are emerging from the Novartis Institutes for BioMedical Research. Novartis said the company has established leadership in three advanced therapy platforms: cell, gene and radioligand therapies, with a total of 16 advanced platform therapies now in clinical development.
The company is prioritizing emerging assets that address significant unmet need. These include iscalimab in transplant and Sjogren's syndrome, LNP023 in renal diseases and PNH, MBG453 in MDS, and TQJ230 in cardiovascular risk reduction. They will be advanced into pivotal trials in the coming years.
Novartis has 60 projects in phase 2 pipeline with more than 10 ...